Exelixis Ripon College Days / Apr 25, 2022
Want to see the real deal?
More inside scoop? View in App
More inside scoop? View in App
FOLLOWING
Show more
Exelixis News
Exelixis Ripon College Days / Apr 25, 2022
<p><span>Vir’s George Scangos, Westlake Village BioPartners’ Sean Harper, Kronos Bio’s Norbert Bischofberger, Scorpion’s Axel Hoos and Eikon’s Roy Baynes discuss the experiences they bring and the challenges they have faced in the transition from large drug makers to small biotechs. </span></p>
Ripon College Days
Exelixis Ripon College Days / Apr 25, 2022
Global Tyrosine Kinase Inhibitors Market Overview: Due to high demand and the value of market resear
Exelixis Ripon College Days / Apr 25, 2022
New York, United States -Report Ocean presents a new report on urinary cancer market size, share, gr
Exelixis Defense World / Apr 22, 2022
New Jersey, United States - The Liver Cancer Treatment Market report is the ultimate tool to he
Exelixis Defense World / Apr 22, 2022
Shares of Exelixis, Inc. (NASDAQ:EXEL – Get Rating) have received an average recommendation of “Buy” from the ten research firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, six have issued a buy rating and one has a…
Defense World
Exelixis Yahoo Finance / Apr 21, 2022
Driven by their blockbuster, Exelixis generated $1.43B in total revenues translating to a 45.3% year-over-year increase. Read more about EXEL stock here.
Exelixis: Beyond The Cabozantinib Franchise
Yahoo Finance
Exelixis Yahoo Finance / Apr 21, 2022
PITTSBURGH & MUMBAI, India, April 21, 2022--TCS inaugurates Pace Port Pittsburgh, a Co-Innovation and Advanced Research Center at Carnegie Mellon University.
Exelixis The Shotcaller The Shotcaller / May 8, 2021
Equities research analysts predict that Exelixis, Inc. (NASDAQ:EXEL) will post earnings of $0.09 per share for the current quarter, Zacks reports. Five analysts have issued estimates for Exelixis’ earnings. The lowest EPS estimate is $0.05 and the highest is $0.12. Exelixis reported earnings of $0.2
Analysts Expect Exelixis, Inc. (NASDAQ:EXEL) Will Post Earnings of $0.09 Per Share
The Shotcaller The Shotcaller
Exelixis The Shotcaller The Shotcaller / May 8, 2021
Proto-Oncogene Drgu Market Outlook 2021-2026|ARIAD Pharmaceuticals, AstraZeneca, Bayer Healthcare, Bristol-Myers Squibb – The Shotcaller The Shotcaller
The Shotcaller The Shotcaller
Exelixis The Pharma Letter / May 5, 2021
US genomics-based drug discovery company Exelixis and French immuno-oncology biotech GamaMabs Pharma... To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space.
Exelixis expands its biotherapeutics portfolio
The Pharma Letter
Exelixis KSU | The Sentinel Newspaper / May 5, 2021
The Liver Cancer Therapeutics market is expected to grow at a CAGR of 6.7% and is poised to reach $XX Billion by 2027 as compared to $XX Billion in 2020. The factors leading to this extraordinary growth is attributed to various market dynamics discussed in the report.
KSU | The Sentinel Newspaper
Exelixis NeighborWebSJ / May 5, 2021
Report is a detailed study of the Neuroendocrine Tumor Treatment market, which covers all the essential information required by a new market entrant as well as the existing players to gain a deeper understanding of the market.The primary objective of this research report named Neuroendocrine Tumor Treatment market is to help making reliable strategic decisions regarding the opportunities in Neuroendocrine Tumor Treatment market.
Exelixis SoccerNurds / May 5, 2021
LOS ANGELES, United States: QY Research offers an overarching research and analysis-based study on, "Global Transitional Cell Cancer Therapeutics Market Report, History and Forecast 2015-2026, Breakdown Data by Companies, Key Regions, Types and Application ". The research report gives the potential headway openings that prevails in the global Transitional Cell Cancer Therapeutics market.
Exelixis SoccerNurds / May 4, 2021
LOS ANGELES, United States: QY Research offers an overarching research and analysis-based study on, "Global Follicular Thyroid Cancer Drug Industry Research Report, Growth Trends and Competitive Analysis 2021-2027 ". The research report gives the potential headway openings that prevails in the global Follicular Thyroid Cancer Drug market.
Exelixis NeighborWebSJ / May 4, 2021
Report is a detailed study of the Antihormonal Cancer Therapies market, which covers all the essential information required by a new market entrant as well as the existing players to gain a deeper understanding of the market.The primary objective of this research report named Antihormonal Cancer Therapies market is to help making reliable strategic decisions regarding the opportunities in Antihormonal Cancer Therapies market.
Exelixis MarketBeat / May 3, 2021
Exelixis, Inc. (NASDAQ:EXEL) - Oppenheimer lowered their Q1 2021 earnings estimates for shares of Exelixis in a note issued to investors on Wednesday, April 28th. Oppenheimer analyst J. Olson now anticipates that the biotechnology company will post earnings per share of $0.07 for the quarter, dow
MarketBeat
Exelixis SoccerNurds / May 3, 2021
The Renal Cell Cacinoma Drugs Market research report aims to provide the readers with an accurate and data-based assessment of the current market conditions over the forecast period of 2021 to 2027. It also provides valuable insight into the market performance in years to come, drawn from a careful assessment of various economic, social, technological, political, and demographic factors.
Exelixis KSU | The Sentinel Newspaper / May 3, 2021
The Liver Cancer Therapeutic Market is expected to grow at a CAGR of 6.1% and is poised to reach US$XX Billion by 2027 as compared to US$XX Billion in 2020. The factors leading to this extraordinary growth is attributed to various market dynamics discussed in the report.
Exelixis SoccerNurds / May 3, 2021